Ginger Janow1, Laura E Schanberg2, Soko Setoguchi2, Victor Hasselblad2, Elizabeth D Mellins2, Rayfel Schneider2, Yukiko Kimura2. 1. From the Division of Pediatric Rheumatology, Joseph M. Sanzari Children's Hospital, Hackensack, New Jersey; Pediatric Rheumatology, Duke University, and Duke Clinical Research Institute, Durham, North Carolina; Pediatric Rheumatology, Stanford University, Stanford, California, USA; Pediatric Rheumatology, Hospital for Sick Children; University of Toronto, Toronto, Ontario, Canada.G. Janow, MD, MPH, Pediatrics, Joseph M. Sanzari Children's Hospital; L.E. Schanberg, MD, Pediatrics, Duke University, and the Duke Clinical Research Institute; S. Setoguchi, MD, PhD, Duke Clinical Research Institute; V. Hasselblad, PhD, MS, Duke Clinical Research Institute; E.D. Mellins, MD, Pediatrics, Stanford University; R. Schneider, MD, Pediatrics, Hospital for Sick Children, and the University of Toronto; Y. Kimura, MD, Pediatrics, Joseph M. Sanzari Children's Hospital. gjanow@hackensackumc.org. 2. From the Division of Pediatric Rheumatology, Joseph M. Sanzari Children's Hospital, Hackensack, New Jersey; Pediatric Rheumatology, Duke University, and Duke Clinical Research Institute, Durham, North Carolina; Pediatric Rheumatology, Stanford University, Stanford, California, USA; Pediatric Rheumatology, Hospital for Sick Children; University of Toronto, Toronto, Ontario, Canada.G. Janow, MD, MPH, Pediatrics, Joseph M. Sanzari Children's Hospital; L.E. Schanberg, MD, Pediatrics, Duke University, and the Duke Clinical Research Institute; S. Setoguchi, MD, PhD, Duke Clinical Research Institute; V. Hasselblad, PhD, MS, Duke Clinical Research Institute; E.D. Mellins, MD, Pediatrics, Stanford University; R. Schneider, MD, Pediatrics, Hospital for Sick Children, and the University of Toronto; Y. Kimura, MD, Pediatrics, Joseph M. Sanzari Children's Hospital.
Abstract
OBJECTIVE: We aimed to identify the (1) demographic/clinical characteristics, (2) medication usage trends, (3) variables associated with worse disease activity, and (4) characteristics of patients with persistent chronic arthritis in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Legacy Registry's systemic juvenile idiopathic arthritis (sJIA) cohort. METHODS: Demographics, disease activity measures, and medications at enrollment of patients with sJIA in the CARRA Registry were analyzed using descriptive statistics. Multivariate analyses were conducted to identify associations with increased disease activity. Medication usage frequencies were calculated by year. RESULTS: There were 528 patients with sJIA enrolled in the registry (2010-2013). There were 435 patients who had a complete dataset; of these, 372 met the International League of Associations for Rheumatology criteria and were included in the analysis. At enrollment, median disease duration and joint count were 3.7 years and 0, respectively; 16.4% had a rash and 6.7% had a fever. Twenty-six percent were taking interleukin 1 (IL-1) inhibitors and 29% glucocorticoids. Disease-modifying antirheumatic drugs and tumor necrosis factor inhibitors use decreased, while IL-6 inhibitor use increased between 2010 and 2013. African American patients had worse joint counts (p = 0.003), functional status (p = 0.01), and physician's global assessment (p = 0.008). Of the 255 subjects with > 2 years of disease duration, 56% had no arthritis or systemic symptoms, while 32% had persistent arthritis only. CONCLUSION: Most patients in the largest sJIA cohort reported to date had low disease activity. Practice patterns for choice of biologic agents appeared to change over the study period. Nearly one-third had persistent arthritis without systemic symptoms > 2 years after onset. African Americans were associated with worse disease activity. Strategies are needed to improve outcomes in subgroups with poor prognosis.
OBJECTIVE: We aimed to identify the (1) demographic/clinical characteristics, (2) medication usage trends, (3) variables associated with worse disease activity, and (4) characteristics of patients with persistent chronic arthritis in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Legacy Registry's systemic juvenile idiopathic arthritis (sJIA) cohort. METHODS: Demographics, disease activity measures, and medications at enrollment of patients with sJIA in the CARRA Registry were analyzed using descriptive statistics. Multivariate analyses were conducted to identify associations with increased disease activity. Medication usage frequencies were calculated by year. RESULTS: There were 528 patients with sJIA enrolled in the registry (2010-2013). There were 435 patients who had a complete dataset; of these, 372 met the International League of Associations for Rheumatology criteria and were included in the analysis. At enrollment, median disease duration and joint count were 3.7 years and 0, respectively; 16.4% had a rash and 6.7% had a fever. Twenty-six percent were taking interleukin 1 (IL-1) inhibitors and 29% glucocorticoids. Disease-modifying antirheumatic drugs and tumornecrosis factor inhibitors use decreased, while IL-6 inhibitor use increased between 2010 and 2013. African American patients had worse joint counts (p = 0.003), functional status (p = 0.01), and physician's global assessment (p = 0.008). Of the 255 subjects with > 2 years of disease duration, 56% had no arthritis or systemic symptoms, while 32% had persistent arthritis only. CONCLUSION: Most patients in the largest sJIA cohort reported to date had low disease activity. Practice patterns for choice of biologic agents appeared to change over the study period. Nearly one-third had persistent arthritis without systemic symptoms > 2 years after onset. African Americans were associated with worse disease activity. Strategies are needed to improve outcomes in subgroups with poor prognosis.
Authors: Peter A Nigrovic; Timothy Beukelman; George Tomlinson; Brian M Feldman; Laura E Schanberg; Yukiko Kimura Journal: Clin Trials Date: 2018-03-15 Impact factor: 2.486
Authors: Lauren A Henderson; Kacie J Hoyt; Pui Y Lee; Deepak A Rao; A Helena Jonsson; Jennifer P Nguyen; Kayleigh Rutherford; Amélie M Julé; Louis-Marie Charbonnier; Siobhan Case; Margaret H Chang; Ezra M Cohen; Fatma Dedeoglu; Robert C Fuhlbrigge; Olha Halyabar; Melissa M Hazen; Erin Janssen; Susan Kim; Jeffrey Lo; Mindy S Lo; Esra Meidan; Mary Beth F Son; Robert P Sundel; Matthew L Stoll; Chad Nusbaum; James A Lederer; Talal A Chatila; Peter A Nigrovic Journal: JCI Insight Date: 2020-03-26
Authors: Gail H Deutsch; R Paul Guillerman; Johannes Birgmeier; Karthik Jagadeesh; Scott Canna; Grant Schulert; Vivian E Saper; Guangbo Chen; Robin Deterding; Jianpeng Xu; Ann N Leung; Layla Bouzoubaa; Khalid Abulaban; Kevin Baszis; Edward M Behrens; James Birmingham; Alicia Casey; Michal Cidon; Randy Q Cron; Aliva De; Fabrizio De Benedetti; Ian Ferguson; Martha P Fishman; Steven I Goodman; T Brent Graham; Alexei A Grom; Kathleen Haines; Melissa Hazen; Lauren A Henderson; Assunta Ho; Maria Ibarra; Christi J Inman; Rita Jerath; Khulood Khawaja; Daniel J Kingsbury; Marisa Klein-Gitelman; Khanh Lai; Sivia Lapidus; Clara Lin; Jenny Lin; Deborah R Liptzin; Diana Milojevic; Joy Mombourquette; Karen Onel; Seza Ozen; Maria Perez; Kathryn Phillippi; Sampath Prahalad; Suhas Radhakrishna; Adam Reinhardt; Mona Riskalla; Natalie Rosenwasser; Johannes Roth; Rayfel Schneider; Dieneke Schonenberg-Meinema; Susan Shenoi; Judith A Smith; Hafize Emine Sönmez; Matthew L Stoll; Christopher Towe; Sara O Vargas; Richard K Vehe; Lisa R Young; Jacqueline Yang; Tushar Desai; Raymond Balise; Ying Lu; Lu Tian; Gill Bejerano; Mark M Davis; Purvesh Khatri; Elizabeth D Mellins Journal: Ann Rheum Dis Date: 2019-09-27 Impact factor: 19.103
Authors: Justine Maller; Emily Fox; K T Park; Sarah Sertial Paul; Kevin Baszis; Charlotte Borocco; Sampath Prahalad; Pierre Quartier; Adam Reinhardt; Dieneke Schonenberg-Meinema; Lauren Shipman-Duensing; Maria Teresa Terreri; Julia Simard; Idit Lavi; Elizabeth Chalom; Joyce Hsu; Devy Zisman; Elizabeth D Mellins Journal: J Rheumatol Date: 2020-06-15 Impact factor: 4.666
Authors: Rosemary G Peterson; Rui Xiao; Karen E James; Hannah Katcoff; Brian T Fisher; Pamela F Weiss Journal: Arthritis Care Res (Hoboken) Date: 2021-10-07 Impact factor: 4.794